ArticleFrontiers in pharmacology2026
Mechanistic study of Shenge powder on myocardial hypertrophy and cardiac lymphatic intervention in TAC-induced mouse models.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the therapeutic effect and mechanism of Shenge Powder (SGS) on myocardial hypertrophy and cardiac lymphangiogenesis using a transverse aortic constriction (TAC) mouse model and a TNF-α-induced lymphatic endothelial cell (LEC) proliferation model. Methods: C57BL/6J mice were randomly divided into sham surgery group and model group (Build molds for 2, 4, 6, 8 weeks respectively) for dynamic observation. Based on this, 4-week C57BL/6J mice were randomly divided into model group, SGS group (low-, medium-, high-dose group), and positive control drug (LCZ696) group. Evaluate lymphangiogenesis and ventricular remodeling through echocardiography, histopathology, transcriptomics, proteomics, and Results: The heart function and epicardial lymphatic vessels of the model group mice showed a compensatory increase in the 2-week and a significant decrease in the 4-week. As the modeling time prolongs, myocardial cell hypertrophy, inflammatory infiltration, interstitial fibrosis, and reduced lymphangiogenesis appear. SGS intervention significantly improves heart function and lymphatic regeneration, reduces myocardial hypertrophy and fibrosis. Transcriptomic analysis revealed that heart failure changes a series of biological functions from compensatory to decompensated phase, affecting multiple signaling pathways including ECM receptor interactions and TGF-β signaling. After TAC modeling, the RT-qPCR results showed that the mRNA expression levels of BNP, α-SMA, Collagen I, Collagen III, TGF-β1, Smad3, VEGFC, and VEGFR-3 were significantly increased. Western blot results showed that the protein expression levels of TGF-β1, P-Smad3, and Smad3 were increased, VEGFC and VEGFR-3 increased in the 2-week and then decreased. After administration of SGS, the mRNA expression of BNP, α-SMA, Collagen I, Collagen III, TGF-β1, and Smad3 was downregulated, while VEGFC and VEGFR-3 was upregulated. The protein expression of TGF-β1, P-Smad3/Smad3 was downregulated, while VEGFC and VEGFR-3 was upregulated. Conclusion: Early compensatory cardiac function enhancement and increased lymphangiogenesis were observed in TAC model mouse, followed by cardiac dysfunction, myocardial hypertrophy, myocardial fibrosis, and decreased lymphangiogenesis. SGS can significantly improve ventricular remodeling and lymphangiogenesis, and its mechanism may be related to inhibiting the TGF-β1/Smad3 pathway and promoting the VEGFC/VEGFR-3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.